Literature DB >> 6340050

Verapamil: an effective calcium blocking agent for pediatric patients.

C J Porter, A Garson, P C Gillette.   

Abstract

Verapamil is a slow-channel calcium-blocking agent that has been released recently by the Food and Drug Administration for treatment of cardiac dysrhythmias in all age groups. Its primary action is to slow conduction in the atrioventricular node, thereby abolishing those types of supraventricular tachycardia using the atrioventricular node as a part of the reentry circuit or slowing the ventricular rate in someone with atrial flutter. Other investigations have shown that it is likely to relieve left ventricular outflow obstruction in patients with hypertrophic obstructive cardiomyopathy. Because of its potential widespread usefulness in the pediatric population, all pediatricians should be more aware of how it is used and the potential hazards. The methods of administration and treatment of overdoses as well as indications for usage, contraindications, and adverse reactions will be explained.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6340050

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

Review 1.  Safety issues in the treatment of paediatric supraventricular tachycardias.

Authors:  J P Pfammatter; U Bauersfeld
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

2.  [Non-invasive treatment of tachycardias during childhood].

Authors:  Jan-Hendrik Nürnberg; Joachim Hebe; Jürgen Siebels
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2014-09

Review 3.  A review of calcium channel antagonists in the treatment of pediatric hypertension.

Authors:  Shobha Sahney
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

4.  Nebulised sodium cromoglycate and verapamil in methacholine induced asthma.

Authors:  A L Boner; G Vallone; A Andreoli; R Biancotto; J O Warner
Journal:  Arch Dis Child       Date:  1987-03       Impact factor: 3.791

5.  Comparison of the effects of inhaled calcium antagonist verapamil, sodium cromoglycate and ipratropium bromide on exercise-induced bronchoconstriction in children with asthma.

Authors:  A L Boner; I Antolini; A Andreoli; G De Stefano; L Sette
Journal:  Eur J Pediatr       Date:  1987-07       Impact factor: 3.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.